Related Experiment Video
Updated: May 8, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas
James J Steinhardt1, Ronald B Gartenhaus
11Marlene & Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland; and 2Veterans Administration Medical Center, Baltimore, Maryland.
Cancer Discovery
|September 11, 2013
Summary
Low-dose DNA methyltransferase inhibitors show promise for resensitizing relapsed diffuse large B-cell lymphoma (DLBCL) to chemotherapy. This epigenetic approach offers a potential neoadjuvant strategy for improving patient survival in refractory DLBCL cases.
Area of Science:
- Oncology
- Epigenetics
- Hematology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
- Chemoresistance in relapsed DLBCL presents a significant challenge to patient survival.
- Epigenetic dysregulation is linked to aggressive cancers and treatment resistance.
Purpose of the Study:
- To investigate the efficacy of low-dose DNA methyltransferase inhibitors in chemosensitizing DLBCL.
- To evaluate epigenetic modifiers as a neoadjuvant therapy for DLBCL.
- To address the challenge of refractory disease in diffuse large B-cell lymphoma.
Main Methods:
- Utilized low-dose DNA methyltransferase inhibitors.
- Assessed the neoadjuvant potential of epigenetic therapy.
- Focused on chemosensitization in DLBCL models.
Main Results:
- Demonstrated the effectiveness of low-dose DNA methyltransferase inhibitors.
- Showcased the potential for epigenetic drugs to resensitize DLBCL to chemotherapy.
- Identified a rational neoadjuvant strategy for DLBCL treatment.
Conclusions:
- Low-dose DNA methyltransferase inhibitors represent a promising strategy for DLBCL chemosensitization.
- Epigenetic therapy can be a rational neoadjuvant approach for refractory DLBCL.
- This study offers a potential new avenue for improving survival in DLBCL patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...